Inhibiting infectious viral titers in cell culture and animal models using vsiRNA as an antiviral method is possible, according to the current study. While this proof-of-concept study backs up the strategy, further work on the strategy is necessary to deliver effective countermeasure solutions. To do this, vsiRNAs that can target different regions of the viral genome must be combined logically in order to increase the extent of inhibition and reduce the risk of suppressive mutations in the viral genome. By boosting bioavailability in difficult-to-reach target tissues like the brain and giving enhanced stability in vivo, optimization of delivery techniques like encapsulation can advance the countermeasure development path.